Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
AEF0217-102 clinical trial assesses the safety, tolerability, plasma exposure and preliminary
indications of pharmacodynamic activity of AEF0217 in female and male adult participants with
Down syndrome between 18 and 35 years old.
The trial AEF0217-102 is a double-blind, randomized, placebo-controlled, multiple-dose,
4-week phase 1/2 study. After a screening period, the participant will be randomised and will
take an oral dose of AEF0217 0.2mg or placebo once a day for 28 days.